MedTrace Logo

Molecular Screening Method for Preeclampsia (PREMOM)

NCT04990141 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9586

Last updated 2025-03-25

No results posted yet for this study

Summary

Preeclampsia (PE) is a major obstetric complication with short- and long-term consequences for the mother and the fetus. Early screening tools to reduce its mortality and morbidity, as well as to prevent the life-threatening consequences are needed. Thus, the detection of women at risk of suffering PE is key to apply preventive and treatment strategies. Recently, the maternal contribution to PE based on defective decidualization has been evidenced and new technical approaches developed to detect circulating biomolecules in blood such as RNA fragments. The main objective of this study is to evaluate the diagnostic precision of the molecular profile from the maternal blood analysed for the early screening of early onset preeclampsia (EOPE).

Conditions

Interventions

PROCEDURE

Peripheral blood collection in cases group

Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in cases group

PROCEDURE

Peripheral blood collection in control group

Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in control group

Sponsors & Collaborators

  • iPremom

    lead INDUSTRY

Principal Investigators

  • Tamara Garrido, PhD · iPremom (Igenomix Preeclampsia SLU)

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-23
Primary Completion
2024-03-27
Completion
2024-03-27

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04990141 on ClinicalTrials.gov